Ocugen

With the successful completion of enrollment in the GARDian3 Phase 2/3 pivotal trial for Stargardt disease, Ocugen expects to file BLA by mid-2027. Read more: bit.ly/4bLcNld #Stargardt #GeneTherapy #InheritedRetinalDiseases #BlindnessDiseases

Our one-time gene therapies target 100s of mutations and address the $132B annual burden of #visionloss. “Probably 100 years from now, they’ll say #genetherapy was one of the greatest discoveries of the 21st century.” – CEO @drsmusunuri in @PharmaVoice bit.ly/4sEc6A1

On #DoctorsDay, we thank the retinal surgeons advancing modifier gene therapy through their work in our clinical trials and serving as our advisors. Your work brings hope to patients facing major blindness diseases where few or no options exist. #GeneTherapy #Biotech

During #WorldOptometryWeek, we recognize the power of collaboration in expanding access to eye care. At Ocugen, we are driving gene therapy innovation for major blindness diseases to help address critical unmet needs in vision care. @WorldCouncilOpt #EyeHealth #GeneTherapy

Today, CEO @drsmusunuri shares encouraging 12-month Phase 2 results for #OCU410 in GA, showing impact on lesion growth and visual function. A one-time gene therapy approach with potential to shift the landscape and address unmet needs.   Read more: bit.ly/4lLGXYV

Ocugen will host a live webcast Mar 24 at 8 a.m. EDT on Phase 2 ArMaDa data for #OCU410 in GA, led by KOLs Lejla Vajzovic, MD, and Jay Chhablani, MD. Don’t miss key insights into advancements in modifier gene therapy for retinal disease. Details: bit.ly/4uJ8GgG

Imagine your vision slowly fading. For millions, this is reality. Early detection and routine eye exams are key. This #SaveYourVisionMonth, Ocugen is advancing innovation through our novel modifier gene therapies that addresses major blindness diseases. #EyeHealth #GeneTherapy

Celebrating the 115th anniversary of #InternationalWomensDay. We recognize the women of Ocugen whose expertise, leadership, and dedication help advance innovation and our mission to deliver transformative novel modifier gene therapies to patients. #IWD2026 #GiveToGain

Behind every step forward at Ocugen is a dedicated team. On #EmployeeAppreciationDay, we recognize the passion, skills, and collaboration of our employees who help move our gene therapy programs forward. Thank you for the teamwork that makes our progress possible. #TeamOcugen

Ocugen welcomes Paul Staid as EVP of Operations! With 20+ years in biologics & gene therapy operations, he will lead supply chain, manufacturing, quality, and digital strategies and support our transition toward regulatory approvals and commercialization. #BiotechLeadership

Ocugen closes 2025 with major milestones: #OCU400 Phase 3 complete for RP, #OCU410ST advancing, positive #OCU410 Phase 2 for #dryAMD, first OCU400 licensing deal, and strengthened leadership. First of three BLA filings ahead! @drsmusunuri #Biotech Read: bit.ly/46BKgeN

Enrollment is now complete for the Phase 3 liMeliGhT trial of #OCU400 for #retinitispigmentosa, the first and largest gene therapy registrational trial for broad RP patients. Ocugen remains on track to file a rolling BLA in 3Q 2026. #Biotech Read more: bit.ly/4lcvktK

We support @RareDiseaseDay! At Ocugen, we are committed to advancing our novel modifier gene therapies for rare inherited retinal diseases with significant unmet needs. We stand with patients, families, and the global #raredisease community, today and every day.

Dr. Gonzalez will present “Safety and Preliminary Efficacy of OCU410ST for Stargardt Disease: Phase 1 Results Update” at the 49th Annual Macula Society Meeting on behalf of Ocugen on Friday, Feb 27, 2026 from 7–7:05 a.m. PST. #GeneTherapy Learn more: bit.ly/4ruCf3R

During #RetinitisPigmentosaAwarenessMonth, the need for new treatments is clear. We are advancing #OCU400, our lead modifier gene therapy candidate, and plan to begin the BLA submission this year. Learn about Manny’s journey: bit.ly/4aQL9Bw #GeneTherapy #Biotech

CEO @drsmusunuri will present at @Oppenheimer's 36th Annual Healthcare Life Sciences Conference tomorrow, Feb 25 from 10:40–11:10 a.m. ET, sharing updates on our novel modifier gene therapies and priorities for the year ahead. #Biotech #Genetherapy

Phase 2 #ArMaDa trial: OCU410 showed a 57% reduction in medium dose and 56% reduction in high dose in lesion growth in patients with baseline GA ≥7.5 mm², suggesting strong benefit in those with more advanced disease. #AMDAwarenessMonth @PBA_savingsight🔗bit.ly/3ZHoMsY

Ocugen will host a conference call & live webcast on Wed, Mar 4 at 8:30 a.m. ET to share the Company’s 4Q & full year 2025 financial results and give a business update. Details: bit.ly/4kE1pu2 #SaveTheDate #InvestorUpdate #Biotech